NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geor
Related Questions
What potential downside risk does the class action investigation pose to UNCY's short-term price performance?
How likely is the lead plaintiff role to be secured by investors and what impact could that have on the stock's liquidity and volatility?
What precedent does this case set for similar biotech firms and could it affect broader sector sentiment or regulatory scrutiny?